Kalhor H, Mokhtarian M, Rahimi H, Shahbazi B, Kalhor R, Komeili Movahed T
Iran J Pharm Res. 2025; 23(1):e150879.
PMID: 40066112
PMC: 11892749.
DOI: 10.5812/ijpr-150879.
Baker J, Nakayama J, OHegarty M, McGowan A, Teran R, Bart S
PLoS One. 2025; 20(1):e0313680.
PMID: 39787187
PMC: 11717262.
DOI: 10.1371/journal.pone.0313680.
Saeed Alqarni Y, Alsulami F, Alhomoud F, Alhomoud F, Alshayban D, Alamer K
J Clin Med. 2025; 13(24.
PMID: 39768534
PMC: 11676101.
DOI: 10.3390/jcm13247610.
Street R, Mathee A, Reddy T, Mahlangeni N, Mangwana N, Nkambule S
Microorganisms. 2024; 12(11).
PMID: 39597619
PMC: 11596097.
DOI: 10.3390/microorganisms12112230.
Duesterwald L, Nguyen M, Christensen P, Long S, Olsen R, Musser J
PLoS One. 2024; 19(10):e0312686.
PMID: 39475880
PMC: 11524481.
DOI: 10.1371/journal.pone.0312686.
Vaccination status and disease severity of COVID-19 in different phases of the pandemic.
Yang X, Shi F, Zhang J, Gao H, Chen S, Olatosi B
Hum Vaccin Immunother. 2024; 20(1):2353491.
PMID: 38832632
PMC: 11152109.
DOI: 10.1080/21645515.2024.2353491.
Relationship between the Viral Load in Patients with Different COVID-19 Severities and SARS-CoV-2 Variants.
Santos Coy-Arechavaleta A, Alvarado-Yaah J, Uribe-Noguez L, Guerra-Castillo F, Santacruz-Tinoco C, Ramon-Gallegos E
Microorganisms. 2024; 12(3).
PMID: 38543479
PMC: 10972047.
DOI: 10.3390/microorganisms12030428.
Factors related to lung function outcomes in critically ill COVID-19 patients in South Korea.
Kim T, Song M, Lim S, Lee Y, Cho Y
Acute Crit Care. 2024; 39(1):100-107.
PMID: 38476063
PMC: 11002626.
DOI: 10.4266/acc.2023.00668.
Computational Modeling Insights into Extreme Heterogeneity in COVID-19 Nasal Swab Data.
Zhang L, Cao H, Medlin K, Pearson J, Aristotelous A, Chen A
Viruses. 2024; 16(1).
PMID: 38257769
PMC: 10820884.
DOI: 10.3390/v16010069.
Association of COVID with Mycosis in General.
Kaur G, Kaur R, Sumanpreet , Kaur M
Infect Disord Drug Targets. 2024; 24(6):e190124225866.
PMID: 38251692
DOI: 10.2174/0118715265266815231130063931.
Comparison of the survival of different isolates of SARS-CoV-2 in evaporating aerosols.
Dabisch P, Wood S, Holland B, Boydston J, Beck K, Green B
Aerosol Sci Technol. 2023; 56(12):1146-1155.
PMID: 38075547
PMC: 10698713.
DOI: 10.1080/02786826.2022.2128712.
Relationships between COVID-19 healthcare outcomes and county characteristics in the U.S. for Delta (B.1.617.2) and Omicron (B.1.1.529 and BA.1.1) variants.
Bruckhaus A, Zhang Y, Salehi S, Abedi A, Duncan D
Front Public Health. 2023; 11:1252668.
PMID: 38045980
PMC: 10693294.
DOI: 10.3389/fpubh.2023.1252668.
A comparison of severity of illness between the SARS-CoV-2 Omicron variant and Delta variant.
Ellis L, Hess O, Huynh K, Bearman G, Kang L, Doern C
Antimicrob Steward Healthc Epidemiol. 2023; 3(1):e188.
PMID: 38028915
PMC: 10654945.
DOI: 10.1017/ash.2023.453.
Digital PCR to Measure SARS-CoV-2 RNA, Variants, and Outcomes in Youth.
Hijano D, Ferrolino J, Gu Z, Brazelton J, Zhu H, Suganda S
J Pediatric Infect Dis Soc. 2023; 12(12):618-626.
PMID: 37956414
PMC: 10725239.
DOI: 10.1093/jpids/piad101.
Disease severity of COVID-19 in different phases of the pandemic: Do healthcare workers have better outcomes?.
Yang X, Shi F, Zhang J, Gao H, Chen S, Olatosi B
Vaccine X. 2023; 15:100377.
PMID: 37681205
PMC: 10480519.
DOI: 10.1016/j.jvacx.2023.100377.
Variant-Specific Viral Kinetics in Acute COVID-19.
Ribeiro R, Choudhary M, Deo R, Giganti M, Moser C, Ritz J
J Infect Dis. 2023; 228(Suppl 2):S136-S143.
PMID: 37650233
PMC: 10469346.
DOI: 10.1093/infdis/jiad314.
Assessing individual risk and the latent transmission of COVID-19 in a population with an interaction-driven temporal model.
Marmor Y, Abbey A, Shahar Y, Mokryn O
Sci Rep. 2023; 13(1):12955.
PMID: 37563358
PMC: 10415258.
DOI: 10.1038/s41598-023-39817-9.
The trend of paediatric cases during the first year of the COVID-19 pandemic in North Sumatra, Indonesia.
Dicky , Marpaung K, Nainggolan I, Hasibuan M, Cahyadi R, Bestari R
IJID Reg. 2023; .
PMID: 37363190
PMC: 9968445.
DOI: 10.1016/j.ijregi.2023.02.006.
Identification of natural killer markers associated with fatal outcome in COVID-19 patients.
Tarantino N, Litvinova E, Samri A, Soulie C, Morin V, Rousseau A
Front Cell Infect Microbiol. 2023; 13:1165756.
PMID: 37342247
PMC: 10277643.
DOI: 10.3389/fcimb.2023.1165756.
SARS-CoV-2 M Protease Variants of Concern Display Altered Viral Substrate and Cell Host Target Galectin-8 Processing but Retain Sensitivity toward Antivirals.
Chen S, Arutyunova E, Lu J, Khan M, Rut W, Zmudzinski M
ACS Cent Sci. 2023; 9(4):696-708.
PMID: 37122453
PMC: 10042146.
DOI: 10.1021/acscentsci.3c00054.
